Novavax settles vaccine dispute, stock rises

Novavax has resolved its financial dispute with Gavi, committing to pay $475 million in cash or vaccines by 2028. This settlement follows a disagreement over canceled vaccine orders, providing stability for the U.S. COVID-19 shot manufacturer.

Articles published about this story
More stories